We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Mini-Review

3-fluoro-GABA enantiomers: exploring the conformation of GABA binding to GABAA receptors and GABA aminotransferase

    David O’Hagan

    School of Chemistry, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK.

    Search for more papers by this author

    Email the corresponding author at do1@st-andrews.ac.uk

    Published Online:11 Feb 2011https://doi.org/10.4155/fmc.10.295

    Abstract

    The neurotransmitter GABA is the main inhibitory neurotransmitter of the CNS. It is estimated that 20–50% of all neuronal synapses are GABAergic. Distinct types of GABA receptor have been identified (GABAA, GABAB and GABAAOr [GABAC]). The GABAA and GABAAOr variant found in the retina receptors (informally termed GABAC) are physiologically related in that they are both ligand (GABA)-gated chloride ion channels. The GABAB receptor mediates its response by modulating Ca2+ and K+ ion channels, which then trigger coupled G-proteins. These receptors have not succumbed to x-ray structural analysis at a suitable resolution to determine the nature of GABA binding. However, knowledge of how GABA binds is important for the design of novel agonists and antagonists, and the development of neuropharmaceutical agents. Comparison of the relative agonistic efficacy of the (R)- and (S)-enantiomers of 3-fluoro-GABA has been used as a method to probe the binding conformation of the neurotransmitter binding to target proteins. The analysis relies on the stereoelectronic influence of the C–F bond interacting with the ammonium group of GABA, an electrostatic interaction that favors solution conformers where the substituents come close (gauche rather than anti). This article describes how comparative analysis of these enantiomers has been used to assess the conformation of GABA binding to GABAA and the GABA-metabolizing enzyme, GABA transaminase.

    Bibliography

    • 1  Murray CW, Rees DC. The rise of fragment-based drug discovery. Nature Chem.1,187–192 (2009).
      Medline CASGoogle Scholar
    • 2  Deniau G, Slawin AM, Lebl T et al. Synthesis, conformation and biological evaluation of the enantiomers of 3-fluoro γ-aminobutyric acid ((R)- and (S)- 3F-GABA). An analogue of the neurotransmitter, GABA. ChemBioChem8,2265–2274 (2007).
      Medline CASGoogle Scholar
    • 3  Clift DC, Haitao J, Deniau GP, O’Hagan D, Silverman RB. Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for g-aminobutyric acid aminotransferase. Conformational probes for GABA binding. Biochemistry46,13819–13828 (2007).
      Medline CASGoogle Scholar
    • 4  Chebib M, Johnston GA. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J. Med. Chem.43,1427–1447 (2000).
      Medline CASGoogle Scholar
    • 5  Clayton T, Chen JL, Ernst M et al. An updated unified pharmacophore model of the benzodiazepine binding site on GABAA receptors: correlation with comparative models. Curr. Med. Chem.14,2755–2775 (2007).
      Medline CASGoogle Scholar
    • 6  Schwenk J, Metz M, Zolles G et al. Native GABAB receptors are hereomultimers with a family of auxiliary subunits. Nature465,231–237 (2010).
      Medline CASGoogle Scholar
    • 7  Abdel-Halim H, Hanrahan JR, Hibbs DE, Johnson GAR, Chebib M. A molecular basis for the agonist and antagonist actions at GABAC receptors. Chem. Biol. Drug. Des.71,306–327 (2008).
      Medline CASGoogle Scholar
    • 8  Allan RD, Fong J. Synthesis of analogues of GABA: XV. Preparation and resolution of some potent cyclopentene and cyclopentane derivatives. Aust. J. Chem.39,855–864 (1986).
      CASGoogle Scholar
    • 9  Chebib M, Duke RK, Allan RD, Johnston GA. The effects of cyclopentane and cyclopentene analogues of GABA at recombinant GABAC receptors. Eur. J. Pharmacol.430,185–192 (2001).
      Medline CASGoogle Scholar
    • 10  O’Hagan D. Understanding organofluorine chemistry. An introduction to the C–F bond. Chem. Soc. Rev.37,308–319 (2008).
      MedlineGoogle Scholar
    • 11  Sun AM, Lankin DC, Hardcastle K, Snyder JP. 3-fluoropiperidines and N-methyl-3-fluoropiperidinium salts. The persistence of axial fluorine. Chem. Eur. J.11,1579–1591 (2005).
      Medline CASGoogle Scholar
    • 12  Gooseman NE, O’Hagan D, Peach MJ, Slawin AM, Tozer DJ, Young RJ. An electrostatic gauche effect in β-fluoro- and β-hydroxy- N-ethylpyridinium cations. Angew. Chemie. Int. Ed.46,5904–5908 (2007).
      Medline CASGoogle Scholar
    • 13  Singh RP, Shreeve JM. Nucleophilic fluorination of amino alcohols and diols using deoxofluor. J. Fluorine Chem.116,23–26 (2002).
      CASGoogle Scholar
    • 14  O’Hagan D, Rzepa HS, Schüler M, Slawin AM. The vicinal difluoro motif. The synthesis and conformation of erythro- and threo- diastereoisomers of 1,2-difluorodiphenylethanes, 2,3-difluorosuccinic acids and their derivatives. Beilstein J. Org. Chem.2,19 (2006).
      MedlineGoogle Scholar
    • 15  Morgenthaler M, Schweizer E, Hoffmann-Röder A et al. Predicting and tuning physicochemical properties in lead optimisation: amine basicities. ChemMedChem2,1100–1115 (2007).
      Medline CASGoogle Scholar
    • 16  Callachan H, Cottrell GA, Hather NY, Lambert JJ, Mooney JM, Peters JJ. Modulation of the GABAA receptor by projesterone metabolites. Proc. R. Soc. London B231,359–369 (1987).
      Medline CASGoogle Scholar
    • 17  Seal RP, Edwards RH. Functional implications of neurotransmitter co-release: glutamate and GABA share the load. Curr. Opin. Pharmacol.6,114–119 (2006).
      Medline CASGoogle Scholar
    • 18  Silverman RB, Levy MA. Substituted 4-aminobutanoic acids. Substrates for γ-aminobutyric acid α-ketoglutaric acid aminotransferase. J. Biol. Chem.256,11565–11568 (1981).
      Medline CASGoogle Scholar